Anne-Marie Girard

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

András Kotschy, Zoltán Szlávik, James B. Murray et al. · Nature · 2016 · 1.1K citations

Medicine, Oncology, Pharmacology +11

In vitro activity of the  -lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases

Therese‐Marie Stachyra, Premavathy Levasseur, Marie-Claude Péchereau et al. · Journal of Antimicrobial Chemotherapy · 2009 · 171 citations · Full text

Life Sciences, Pharmacology, Antimicrobial Pharmacology +16

Mechanism of Action of the Antibiotic NXL101, a Novel Nonfluoroquinolone Inhibitor of Bacterial Type II Topoisomerases

Michael T. Black, Therese‐Marie Stachyra, Denis Platel et al. · Antimicrobial Agents and Chemotherapy · 2008 · 144 citations · Full text

Life Sciences, Microbiology, Pharmacology +16

S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth

Patrick Casara, James Davidson, Audrey Clapéron et al. · Oncotarget · 2018 · 115 citations · Full text

Medicine, Oncology, Pharmacology +17

Discovery of S64315, a Potent and Selective Mcl-1 Inhibitor

Zoltán Szlávik, Márton Csékei, Attila Paczal et al. · Journal of Medicinal Chemistry · 2020 · 106 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17